Neumifil is under clinical development by Pneumagen and currently in Phase II for Influenza A Virus, H1N1 Subtype Infections. According to GlobalData, Phase II drugs for Influenza A Virus, H1N1 Subtype Infections have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Neumifil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neumifil overview
Neumifil is under development for the treatment of Streptococcus pneumococcal meningitis, influenza A virus, H7N9, H1N1 and H5N1 subtype infections, respiratory syncytial virus (RSV) infections and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is isolated form of carbohydrate binding molecule (CBM) from S. pneumoniae NanA. It is administered through intranasal route. It is being developed based on GlycoTarge technology. The drug candidate acts by targeting neuraminidase A (nanA).
It was also under development for pneumococcal meningitis.
Pneumagen overview
Pneumagen, is develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer. The company is headquartered in United Kingdom.
For a complete picture of Neumifil’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
